Skip to content

Acceleron (NASDAQ: XLRN) founded in 2004, is a publicly-traded, clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company's leadership in the understanding of TGF-beta biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.

Latest News from Acceleron Pharma